Plasma treatment for a rare eye condition from Type 1 deficiency
Part of Eyes & vision clinical trials.
This trial studies donated blood-plasma samples as a treatment for ligneous conjunctivitis caused by Type 1 plasminogen deficiency. It may help reduce or improve the eye inflammation and growths linked to this specific genetic problem.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ligneous conjunctivitis.
- Your cause is Type 1 plasminogen deficiency (a specific protein deficiency).
- Your eye condition must allow you to use the study treatment safely.
- You do not have another eye problem at the same time that would block study drug use.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called LX107 for people with vision loss caused by changes in the AIPL1 gene. It aims to see if the treatment is safe and can improve vision.
This trial tests whether an injection of a special concentrate from your own blood (platelet-rich plasma, or PRP) can help calm severe dry eye disease. It’s meant for people whose dry eye has not improved with other treatments.
This study looks at people diagnosed with type 1 plasminogen deficiency (a condition with low plasminogen levels) and can also include their first-degree family members. It may help researchers learn more about the condition and how to monitor it over time by collecting blood and genetic information.
This study compares two types of blood-derived treatments (a growth-factor enriched plasma product versus your own serum) to see which helps corneal cells heal better in people with aniridia. It may be helpful if you need improved cornea healing, but you must meet blood-safety and eye-sample requirements.
This trial tests whether eye drops made from a small sample of your own blood can relieve the symptoms of severe dry eye disease. The drops are meant to help eyes that have not improved with standard treatments.
This Phase 1/2 trial tests a treatment made from your own mouth tissue cells to help regrow the front surface of the eye when both eyes have severe limbal stem cell deficiency. If you qualify, you may receive an autologous (made from your own tissue) cell sheet to improve eye healing and vision.
Hear when a new Ligneous Conjunctivitis, Left Eye trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.